Revelation Biosciences, Inc. Share Price & Technical Analysis
REVB · $1.02 (-3.77%)
Healthcare / Biotechnology
$1.02
-3.77%
Revelation Biosciences, Inc. operates as a clinical-stage life science company that focuses on the rebalancing inflammation to optimize health. The company's lead product candidate is lead product candidate Gemini, a proprietary formulation platform of phosphorylated hexaacyl disaccharide (PHAD), an established Toll-like receptor 4 (TLR) agonist that works by modulating and rebalancing a dysregula…
Price chart
Seasonality
Jun has 1 positive and 2 negative years (last 5 years shown)
0% return in Jun, -7% avg return in past 3 year Jun month.
-83% return in 2026, -207% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | -35% | -32% | -8% | -8% | 0% | 0% | – | – | – | – | – | – | -83% |
| 25 | -79% | -5% | -25% | 17% | -71% | -12% | 11% | 12% | -47% | -11% | -22% | -18% | -250% |
| 24 | -41% | 3% | -24% | -22% | -7% | 0% | -12% | -30% | -25% | -1% | -11% | -46% | -218% |
| 23 | 61% | -77% | -41% | -20% | 2% | -8% | -12% | -20% | 2% | -17% | 10% | -36% | -154% |
| 22 | -75% | -48% | -10% | -17% | -44% | 95% | -47% | -25% | -36% | 10% | -27% | -6% | -232% |
Monthly return % by calendar month · historical pattern, not a forecast
Bearish · Downtrend · Weak
Revelation Biosciences, Inc. operates as a clinical-stage life science company that focuses on the rebalancing inflammation to optimize health. The company's lead product candidate is lead product candidate Gemini, a proprietary formulation platform of phosphorylated hexaacyl disaccharide (PHAD), an established Toll-like receptor 4 (TLR) agonist that works by modulating and rebalancing a dysregulated inflammatory response. It also engages in the prevention and treatment of disease by developing and commercializing therapeutics that modulate the innate immune system, including GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease. The company was formerly known as Petra Acquisition, Inc. and changed its name to Revelation Biosciences, Inc. in January 2022. Revelation Biosciences, Inc. was incorporated in 2019 and is based in San Diego, California.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$4.20M
P/E ratio
—
52W high
$12.88
52W low
$0.88
Volume
46,329
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹34,400
Abbott Laboratories Cede…
₹32,740
Eli Lilly And Company Ce…
₹28,720
Unitedhealth Group Inc C…
₹17,140
Elevance Health Inc
₹6,770
Frequently asked questions
- What is Revelation Biosciences, Inc. share price today?
- Revelation Biosciences, Inc. (REVB) last traded around $1.02 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does REVB have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for REVB. Download the app for real-time alerts.
- How can I analyze Revelation Biosciences, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.